WANBANGDE PHARMACEUTICAL HOLDING GROUP CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.61 CNY | +1.99% |
|
+7.46% | -27.97% |
| Jan. 29 | Wanbangde Pharma Elects Vice Chairman, Appoints CFO | MT |
| Jan. 19 | Wanbangde Pharma's Anesthesia Passes Drug Regulator's Consistency Evaluation | MT |
| Sales 2021 | 1.93B 267M | Sales 2022 | 1.79B 247M | Capitalization | 5.41B 747M |
|---|---|---|---|---|---|
| Net income 2021 | 167M 23.07M | Net income 2022 | 93M 12.85M | EV / Sales 2021 | 4.67 x |
| Net cash position 2021 | 69.54M 9.61M | Net Debt 2022 | 397M 54.82M | EV / Sales 2022 | 3.25 x |
| P/E ratio 2021 |
54.8
x | P/E ratio 2022 |
58.8
x | Employees | 1,569 |
| Yield 2021 * |
-
| Yield 2022 |
1.36% | Free-Float | 44.88% |
More Fundamentals
* Assessed data
More news
| 1 day | +1.99% | ||
| 1 week | +7.46% | ||
| Current month | -7.06% | ||
| 1 month | -6.49% | ||
| 3 months | -20.52% | ||
| 6 months | -29.08% | ||
| Current year | -27.97% |
1 week
4.13
4.62
1 month
4.075.16
Current year
3.706.65
1 year
3.708.07
3 years
3.7017.35
5 years
3.7017.67
10 years
3.7028.89
| Managers | Title | Age | Since |
|---|---|---|---|
Shou Ming Zhao
CEO | Chief Executive Officer | 60 | 17-07-13 |
Tong Ke Liu
BRD | Director/Board Member | 59 | 17-07-13 |
Jian Jiang
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Hu Gen Wang
CHM | Chairman | 75 | 17-07-13 |
Shou Ming Zhao
CEO | Chief Executive Officer | 60 | 17-07-13 |
Tong Ke Liu
BRD | Director/Board Member | 59 | 17-07-13 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-25 | 4.61 | +1.99% | 5,238,908 |
| 24-04-24 | 4.52 | +3.67% | 4,751,561 |
| 24-04-23 | 4.36 | +3.07% | 4,096,200 |
| 24-04-22 | 4.23 | -0.47% | 3,506,200 |
| 24-04-19 | 4.25 | -0.93% | 3,989,800 |
End-of-day quote Shenzhen S.E., April 24, 2024
More quotes
Wepon Pharmaceutical Holding Group Co Ltd, formerly Wanbangde Pharmaceutical Holding Group Co Ltd, is a China-based company mainly engaged in the manufacture of pharmaceuticals and medical devices. The Company primarily operates through three segments. The Pharmaceutical Manufacturing segment is mainly engaged in the research and development, production and sales of modern Chinese medicines, chemical raw materials and chemical preparations. The Medical Device segment is mainly engaged in the research and development of medical devices, medical equipment services and provision of hospital engineering services. The Company also conducts its business through the Other segment. The Company conducts its business in the domestic and overseas markets.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
| 1st Jan change | Capi. | |
|---|---|---|
| -27.97% | 382M | |
| +19.06% | 22.25B | |
| +13.49% | 14.39B | |
| +12.83% | 13.55B | |
| +38.02% | 11.27B | |
| -10.16% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.35% | 5.01B | |
| -5.36% | 4.51B |
- Stock Market
- Equities
- 002082 Stock
